Hansa Biopharma AB (publ) (HNSBF) to Post Quarterly Earnings on Wednesday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) will likely be announcing its resultson Wednesday, July 22nd. Analysts expect the company to post earnings of ($0.0346) per share and revenue of $5.17 million for the quarter.

Hansa Biopharma AB (publ) Price Performance

OTCMKTS:HNSBF opened at $2.90 on Tuesday. Hansa Biopharma AB has a fifty-two week low of $2.90 and a fifty-two week high of $2.90. The firm’s 50 day moving average is $2.90 and its two-hundred day moving average is $2.90.

Analyst Upgrades and Downgrades

Separately, Danske assumed coverage on shares of Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating for the company. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical?stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor?specific antibodies in highly sensitized kidney transplant patients.